Business Context and Reporting Period
This Form 8-K is a current report filed by EyeGate Pharmaceuticals, Inc. (not Kiora Pharmaceuticals Inc.) on August 20, 2021. The registrant is a Delaware corporation with its principal executive offices in Waltham, MA, and its common stock trades on The Nasdaq Capital Market under the symbol EYEG. The company is classified as an emerging growth company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial statements or performance data.
Material Changes
Under Item 5.02, the company reported the departure of a senior officer:
- Michael Manzo ceased serving as the Vice President of Engineering effective August 20, 2021.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The document is limited to the notification of the executive departure.
Investor Verification Checklist
- Verify the correct registrant name is EyeGate Pharmaceuticals, Inc., not Kiora Pharmaceuticals Inc.
- Confirm the effective date of Michael Manzo's departure (August 20, 2021).
- Check subsequent filings for the appointment of a replacement for the Vice President of Engineering role.
- Review the company's latest 10-Q or 10-K for financial metrics, as this 8-K does not include them.